Express News | Entero Therapeutics Inc: Exploring Strategic Alternatives for Purpose of Maximizing Value of All of Our Stakeholders

ReutersNov 27 17:14 ET

Express News | Entero Therapeutics Inc: Have Reduced Headcount and Paused Development Activities

ReutersNov 27 17:14 ET

Express News | Entero Therapeutics Inc: Acceleration or Reduction of Cash Outflows and Debt Obligations Can Significantly Impact Our Ability to Maintain Operations

ReutersNov 27 17:13 ET

Express News | Entero Therapeutics: On Nov 21, Immunogenx Received Notice of Default, Demand for Payment Relating to Credit Agreement, Dated as of Oct 3, 2022

ReutersNov 27 17:09 ET

Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum

Yahoo FinanceNov 14 08:00 ET

Shareholder Alert: Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

Business WireNov 13 21:45 ET